**Figure 2.** **Prognostic significance of the FRGs signature derived risk scores.** (**A**, **B**) Univariate and multivariate Cox analysis evaluating the prognostic-related genes in the TCGA (**A**) and CGGA cohort (**B**). The Kaplan-Meier survival curves for the high- and low-risk groups in TCGA (**C**) and CGGA cohort (**D**). (**E**, **I**) The predictive efficiency of the FRGs risk signature on the 1-, 3-, and 5-years survival rate in TCGA (**E**) and CGGA cohort (**I**) via ROC curve. (**F**, **J**) Heat maps of these three FRGs (CRYAB, MT1G, STEAP3) expression profiles in TCGA (**F**) and CGGA cohort (**J**). (**G**–**I**, **K**–**L**) Distribution of risk score and patient survival time, and status of GBM in TCGA (**G**, **H**) and CGGA cohort (**K**, **L**). The black dotted line is the optimal cut-off value for dividing patients into low-risk and high-risk groups. (**M**–**P**) Univariate and multivariate Cox analyses for evaluating the independent prognostic value of the FRGs signature in TCGA (**M**, **N**) and CGGA cohort (**O**, **P**).